论文部分内容阅读
目的探讨胺碘酮联合厄贝沙坦对心力衰竭合并心律失常患者的临床疗效。方法 150例心力衰竭合并心律失常患者,按入院时间从1~150依次编号,单号患者分为实验组,双号患者分为对照组,各75例。对照组患者接受常规治疗,实验组在对照组基础上加用厄贝沙坦、胺碘酮治疗,观察两组患者治疗后60、120、180 d的窦性心律维持率,以及治疗前后左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左室射血分数(LVEF)、每搏心输出量(SV)的变化和治疗效果。结果实验组患者治疗后60、120、180 d的窦性心律维持率为74.67%(56/75)、86.67%(65/75)、69.33%(52/75),明显高于对照组的53.33%(40/75)、64.00%(48/75)、60.00%(45/75),差异具有统计学意义(P<0.05)。实验组:治疗前LVESD(57.95±2.85)mm、LVEDD(65.39±3.86)mm、LVEF(33.79±0.92)%、SV(3.07±0.22)L/min,治疗后LVESD(51.11±3.15)mm、LVEDD(56.18±3.23)mm、LVEF(50.32±1.22)%、SV(4.71±0.29)L/min;对照组:治疗前LVESD(58.25±2.75)mm、LVEDD(65.33±3.91)mm、LVEF(33.75±0.87)%、SV(3.11±0.25)L/min,治疗后LVESD(55.09±3.05)mm、LVEDD(60.05±3.17)mm、LVEF(45.63±0.98)%、SV(4.19±0.28)L/min;两组患者治疗前LVESD、LVEDD、LVEF、SV水平比较差异无统计学意义(P>0.05),治疗后实验组LVESD、LVEDD、LVEF、SV水平均优于对照组,差异具有统计学意义(P<0.05)。对照组患者治疗总有效率为82.67%,明显低于实验组的96.00%,差异具有统计学意义(P<0.05)。结论胺碘酮联合厄贝沙坦治疗心力衰竭合并心律失常患者安全有效,临床应用价值较高,值得推广。
Objective To investigate the clinical efficacy of amiodarone combined with irbesartan in patients with heart failure and arrhythmia. Methods A total of 150 patients with heart failure and arrhythmia were numbered from 1 to 150 according to the time of hospitalization. The patients with single number were divided into experimental group and the patients with double number were divided into control group (75 cases each). The patients in the control group received conventional therapy. The experimental group was treated with irbesartan and amiodarone on the basis of the control group. The maintenance rate of sinus rhythm at 60, 120 and 180 days after treatment was observed in both groups, and the left ventricular (LVESD), left ventricular end-diastolic dimension (LVEDD), left ventricular ejection fraction (LVEF), cardiac output per stroke (SV) and the therapeutic effect. Results The maintenance rate of sinus rhythm in the experimental group was 74.67% (56/75), 86.67% (65/75) and 69.33% (52/75) after 60, 120 and 180 days of treatment respectively, which was significantly higher than that of the control group % (40/75), 64.00% (48/75) and 60.00% (45/75), respectively. The difference was statistically significant (P <0.05). In the experimental group, LVESD (57.95 ± 2.85) mm, LVEDD (65.39 ± 3.86) mm, LVEF (33.79 ± 0.92)% and SV (3.07 ± 0.22) L / (56.18 ± 3.23) mm, LVEF (50.32 ± 1.22)% and SV (4.71 ± 0.29) L / min respectively. The control group: LVESD 58.25 ± 2.75 mm, LVEDD 65.33 ± 3.91 mm and LVEF 33.75 ± LVEDD (60.05 ± 3.17) mm, LVEF (45.63 ± 0.98)% and SV (4.19 ± 0.28) L / min, respectively; There was no significant difference in LVESD, LVEDD, LVEF and SV between the two groups before treatment (P> 0.05). After treatment, the levels of LVESD, LVEDD, LVEF and SV in the experimental group were all better than those in the control group (P <0.05). The total effective rate of the control group was 82.67%, which was significantly lower than that of the experimental group (96.00%), the difference was statistically significant (P <0.05). Conclusion Amiodarone combined with irbesartan in the treatment of patients with heart failure and arrhythmia is safe and effective, and has high clinical value and is worthy of promotion.